Talk:Ecopipam

Stuttering
Article should mention its potential in treating stuttering. --2600:1700:3D06:40:1C27:CDAE:EE37:208A (talk) 03:43, 24 September 2020 (UTC)

Stuttering
Ecopipam is also a potantial threatment for stuttering. Article should contain some sentences about stuttering. Alkantenik (talk) 19:17, 21 May 2021 (UTC)

Research for stuttering discontinued
As per the official Emalex announcement:

November 18, 2022

Thank you for signing up for information regarding the Speak Freely research study for adults who have been stuttering since childhood (https://speakfreelyregistry.researchstudytrial.com/). The study conclusions are given below. This initial exploratory clinical research study was to learn whether ecopipam is safe in adults with childhood onset fluency disorder (COFD) and whether ecopipam and the instruments to measure fluency changes are effective. This initial study was not intended to be evaluated by the FDA for prescription approval. A total of 68 participants were eligible and randomized to study drug with 35 participants randomized to ecopipam and 33 randomized to matching placebo. Study conclusions: The most frequent adverse events were somnolence (23.5%), fatigue (8.8%), insomnia (8.8%), and sedation (8.8%). There was a modest numerical improvement in all the instruments used to measure disfluency in participants who received ecopipam compared to participants who received matching placebo, however, the treatment effect was not as large as anticipated. Emalex is not planning to conduct further research studies to develop ecopipam as a possible treatment for COFD. We thank the National Stuttering Association, the participants who volunteered, and the community for their support of this research study. MattSzymanko (talk) 00:06, 29 January 2023 (UTC)